Meeder Asset Management Inc. reduced its stake in shares of Davita Inc (NYSE:DVA) by 13.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,255 shares of the company’s stock after selling 1,696 shares during the period. Meeder Asset Management Inc.’s holdings in Davita were worth $642,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Invesco Ltd. boosted its holdings in Davita by 56.2% in the 2nd quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock worth $206,063,000 after buying an additional 1,317,725 shares during the period. Par Capital Management Inc. boosted its holdings in Davita by 40.6% in the 2nd quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock valued at $233,985,000 after purchasing an additional 1,201,300 shares during the period. Pictet Asset Management Ltd. boosted its holdings in Davita by 3,290.3% in the 2nd quarter. Pictet Asset Management Ltd. now owns 1,132,521 shares of the company’s stock valued at $63,716,000 after purchasing an additional 1,168,020 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Davita by 1,512.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 724,095 shares of the company’s stock valued at $40,159,000 after purchasing an additional 679,199 shares during the period. Finally, Camber Capital Management LP boosted its holdings in Davita by 33.3% in the 2nd quarter. Camber Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $112,520,000 after purchasing an additional 500,000 shares during the period. 90.92% of the stock is owned by institutional investors.
Several research analysts have commented on the stock. Robert W. Baird downgraded shares of Davita from an “outperform” rating to a “neutral” rating and cut their price target for the company from $70.00 to $65.00 in a report on Friday, July 26th. ValuEngine raised shares of Davita from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. William Blair downgraded shares of Davita from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 11th. UBS Group cut their price target on shares of Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Finally, SunTrust Banks reissued a “hold” rating and issued a $68.00 price target on shares of Davita in a report on Wednesday, September 11th. Eight investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $65.35.
Shares of NYSE:DVA opened at $58.69 on Monday. The stock has a market cap of $9.27 billion, a PE ratio of 16.44, a PEG ratio of 0.57 and a beta of 1.60. The company’s fifty day moving average is $58.03 and its 200 day moving average is $55.06. Davita Inc has a 52 week low of $43.40 and a 52 week high of $79.11. The company has a quick ratio of 1.10, a current ratio of 1.12 and a debt-to-equity ratio of 1.90.
Davita (NYSE:DVA) last issued its earnings results on Thursday, August 1st. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.12. The company had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. The firm’s revenue was down 1.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 EPS. Sell-side analysts anticipate that Davita Inc will post 4.78 EPS for the current year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.